Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan

• Published in: The AAPS journal Vol. 26; no. 6; p. 109
• Main Authors: Ishibai, Mitsuru, Kai, Megumi, Wakuda, Hirokazu, Oikawa, Ichiro, Uemura, Naoto
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 08-10-2024; Springer
• Subjects: Adalimumab; Antibodies; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Biochemistry; Biological products; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cross-Sectional Studies; Diseases; Drug Approval; Humans; Japan; Pharmacology/Toxicology; Pharmacy; Research Article; Viral antibodies; Japan; New drug application; Anti-drug antibody; Immunogenicity; Drug loss
• ISSN: 1550-7416; 1550-7416
• DOI: 10.1208/s12248-024-00980-0

Anti-drug antibodies (ADAs) generated in response to biopharmaceuticals can significantly impact pharmacokinetics (PK) and overall drug efficacy. Thus, the ICH M4 guidelines mandate summarizing immunogenicity data from clinical trials in drug approval applications. However, following the approval of the first antibody drug in Japan in 2001, no cross-sectional investigation has focused on immunogenicity during the regulatory review process. Therefore, this study aims to examine the review reports and prescribing information of antibody drugs approved in Japan to identify key points related to immunogenicity evaluation. We conducted a cross-sectional analysis of review reports for antibody drugs approved between June 2001 and July 2022 by the Japanese regulatory authority. Specifically, we evaluated the ADA positivity rate, presence of neutralizing antibodies, antibody titers, and effects of ADA on PK, efficacy, and safety. We also compared this information with that provided in the prescribing information. Our analysis revealed that the ADA positivity rate and its effects on PK, efficacy, and safety were critical aspects of the review process. The emphasis on these factors varied depending on the number of applications and disease area. The information presented in the prescribing information was largely consistent with that discussed in the review reports. Overall, this study provides the first cross-sectional evaluation of immunogenicity considerations in the regulatory review of antibody drugs in Japan. Our findings can contribute to the efficiency of clinical trial planning and preparation of approval applications, to potentially improve the overall drug development process and address the drug loss problem in Japan.
Graphical Abstract